Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY EBITDA Margin

EBITDA as a percentage of revenue.

Eli Lilly and CompanyNYSE: LLY

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 56.5%

EBITDA Margin was 56.5% in Q2 FY2026, up 8.3 pp from a year earlier. On a trailing-twelve-month basis it was 54.4%, up 14.4 pp year over year. Over 3 fiscal years it widened by 18.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 45.3% for the fiscal year ending Dec 2026, down from 48.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
56.5%+4.6 pp QoQ
Last fiscal yearDec 2025
48.6%+6.9 pp YoY
LTMJun 2026
54.4%+14.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.3 pp-14.2 pp-22.5 pp
1 year+6.9 pp-3.4 pp-10.2 pp
3 years+18.3 pp+7.9 pp-10.4 pp
5 years+12.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
48.6%
Year-over-year change
+6.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How LLY compares with its peers on the latest reported figures

  • LLY's LTM Jun 2026 EBITDA Margin of 54.4% is the 2nd highest of the 10 companies compared; the peer median is 34.4%.
  • Its year-over-year change of +14.4 pp is the 2nd highest of 10, against a peer median of -0.5 pp.
  • Over three fiscal years its change of +18.3 pp compares with a peer median of +7.3 pp.
LLY Competitors Peer median
EBITDA Margin for LLY and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202654.9% -0.5 pp+7.3 pp
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
Peer median (excluding LLY) 34.4%-0.5 pp+7.3 pp

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.32B28.54B34.12B45.04B65.18B
Cost of Revenue7.31B6.63B7.08B8.42B11.05B
Gross Profit21.01B21.91B27.04B36.63B54.13B
Gross Margin74.2%76.8%79.2%81.3%83.0%
Research & Development6.93B7.19B9.31B10.99B13.34B
Selling, General & Admin6.14B6.07B6.94B8.59B11.09B
Operating Expenses13.07B13.26B16.25B19.59B24.43B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
EBITDA8.04B8.66B8.57B18.81B31.69B
EBITDA Margin28.4%30.3%25.1%41.8%48.6%
Operating Income7.93B8.65B10.79B17.04B29.7B
Operating Margin28.0%30.3%31.6%37.8%45.6%
Interest Income25.4M62.8M173.6M175.2M153.3M
Interest Expense339.8M331.6M485.9M780.6M795.3M
Other Income / Expenses(1.78B)(1.85B)(4.23B)(4.36B)(3.97B)
Income Before Tax6.16B6.81B6.55B12.68B25.73B
Pre-Tax Margin21.7%23.8%19.2%28.2%39.5%
Income Tax Expense573.8M561.6M1.31B2.09B5.09B
Net Income5.58B6.24B5.24B10.59B20.64B
Net Margin19.7%21.9%15.4%23.5%31.7%
EPS (Basic)5.856.575.8311.7623.07
EPS (Diluted)5.856.575.8011.7122.95
Weighted Avg Shares953.65M950.18M899.38M900.61M898M
Weighted Avg Shares (Diluted)953.65M950.18M903.28M904.06M898M

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.